FDA Asks For ODAC’s Advice On Composite PFS Endpoint for GPC’s Satraplatin

FDA is seeking the Oncologic Drugs Advisory Committee's opinion on using a composite progression-free survival endpoint as the basis for GPC Biotech's application for Orplatna (satraplatin) to treat androgen-independent prostate cancer in men who failed prior chemotherapy once